OVID analyst estimates
Ovid Therapeutics (OVID) analyst ratings, the average price target and its range, and every firm's latest call.
OVID analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 15, 2026 | Wolfe Research | Ovid Therapeutics initiated with an Outperform at Wolfe Research | $5.00 |
| Oct 5, 2026 | Guggenheim | Guggenheim starts Ovid Therapeutics initiated with a Buy on OV329 potential | $7.00 |
| Sep 11, 2026 | H.C. Wainwright | Ovid Therapeutics price target raised to $5 from $4 at H.C. Wainwright | $5.00 |
| Sep 3, 2026 | Roth Capital | Ovid Therapeutics price target raised to $8 from $7 at Roth Capital | $8.00 |
| May 14, 2026 | Roth Capital | Ovid Therapeutics price target raised to $7 from $5 at Roth Capital | $7.00 |
| Apr 9, 2026 | H.C. Wainwright | Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright | $4.00 |
| Dec 11, 2025 | Roth Capital | Ovid Therapeutics initiated with a Buy at Roth Capital | $3.00 |
| Nov 24, 2025 | H.C. Wainwright | Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright | $2.00 |
| Jul 2, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID) | $3.00 |
| May 20, 2024 | BTIG | BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID) | $11.00 |
| May 14, 2024 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Ovid Therapeutics Inc (OVID) | $8.00 |
- 10 firms rate OVID: 10 buy, 0 hold, 0 sell.
- The average price target is $6.25 from 4 analysts, from $5.00 to $8.00.
Updated 2026-11-07 11:50 UTC